Idogen receives orphan drug status for Hemophilia A

Release Date: 13-Feb-2017

European Commission has granted orphan drug designation to Idogen for the treatment of patients with Hemophilia A. The European Commission grants orphan drug designation status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the European Union. The orphan drug designation provides Abeona with incentives and benefits in the EU, including protocol assistance, reduced fees and protection from market competition once ABO-101 is approved for the treatment of MPS IIIB patients.


For Orphan Drug Clinical Insight Reports Contact:

Need custom market research solution? We can help you with that too.